HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Chronic myeloid leukemia (CML) is manageable with imatinib targeting BCR-ABL, but resistance develops in 15-20% of patients.
• Imatinib resistance in CML leads to disease progression and poor outcomes, necessitating alternative therapies.
• Histone deacetylase inhibitors (HDACis) are being explored for their anticancer potential.

Purpose of the Study:

• To investigate the efficacy of HDAC inhibitors as a potential therapy for imatinib-resistant CML (IR-CML).
• To determine the mechanism by which HDAC inhibitors induce apoptosis in CML and IR-CML cells.
• To assess the role of specific HDACs (HDAC1 and HDAC2) in CML cell survival.

Main Methods:

• Utilized a noninvasive apoptosis detection sensor (NIADS) to measure cell death.
• Treated K562 and imatinib-resistant K562 (IR-K562) cells with panobinostat.
• Employed CRISPR/Cas9 genomic editing to knock out HDAC1 and HDAC2 genes.
• Analyzed histone acetylation (H3 and H4) to understand drug mechanisms.

Main Results:

• Panobinostat significantly enhanced apoptosis in K562 cells.
• Panobinostat induced apoptosis in both K562 and IR-K562 cells, primarily through H3 and H4 histone acetylation.
• Panobinostat demonstrated targeting of cancer stem cells (CSCs) within IR-K562 cells.
• Knockout of HDAC1 and HDAC2 using CRISPR/Cas9 significantly induced apoptosis in K562 cells.

Conclusions:

• HDAC inhibitors, such as panobinostat, offer therapeutic benefits for both CML and imatinib-resistant CML.
• Targeting HDAC activity, specifically HDAC1 and HDAC2, is crucial for CML cell survival and represents a viable therapeutic strategy.
• HDAC inhibitors provide a promising approach to overcome imatinib resistance in CML patients.